AbbVie Inc. (NYSE:ABBV) is included among the

13 Best Roth IRA Stocks to Buy Now.

On February 5, Evercore ISI analyst Gavin Clark-Gartner cut his price recommendation on AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained an outperform rating on the stock. In a note to investors, he said that while Tremfya continues to gain share, guidance and consensus expectations for 2026 still look better, and the same applies to 2027. He also wrote that it’s worth noting that buy expectations have been above consensus for some time and margin performance is more limited. around growth beyond 2028, especially as more competitors enter the market.

AbbVie on Feb. 4 projected 2026 profit above Wall Street estimates after reporting fourth-quarter results that beat expectations. The pace of earnings was largely driven by stronger-than-expected sales of its older immunology drug, Humira. Still, shares dipped in morning trading that day as investors reacted to a revenue shortfall from Rinvoq, one of the company’s newest immunology treatments, and raised concerns about the durability of its future growth drivers. AbbVie has been counting on Skyrizi and Rinvoq to offset continued declines in Humira sales, which have been pressured by lower-cost biosimilars. Humira had once been the world’s best-selling drug, reaching peak global sales of more than $21 billion by 2022 before losing US patent protection.

In the fourth quarter, Skyrizi generated $5.01 billion in sales, ahead of the $4.82 billion analysts expected. Rinvoq posted $2.37 billion, slightly below the consensus estimate of $2.41 billion, according to LSEG data. The earnings outperformance was supported by Humira, which saw sales decline 25.9% year over year to $1.25 billion, but still beat expectations of $983.8 million. The drug is off patent and is expected to continue to decline.

Looking ahead, AbbVie expects Rinvoq and Skyrizi to generate approximately $31.6 billion in combined revenue by 2026, reaching its goal of more than $31 billion in combined annual sales a year ahead of schedule.

AbbVie Inc. (NYSE:ABBV) is a research-based global biopharmaceutical company engaged in the development, manufacture and commercialization of medicines. Its portfolio spans immunology, oncology, aesthetics, neuroscience, eye care and other key therapeutic areas.